Cassava Sciences Inc vs RLX Technology Inc — how do they compare? Cassava Sciences Inc trades at $0.95 (market cap $47.75M), while RLX Technology Inc trades at $2.03 (market cap $2.42B). The key difference: RLX Technology Inc is far larger — about 50.7× Cassava Sciences Inc's market cap, and RLX Technology Inc pays a 5.05% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | RLX | |
|---|---|---|
Market Cap | $47.75M | $2.42B |
Sector | Health | Technology |
52-Week High | $4.64 | $2.73 |
52-Week Low | $0.87 | $1.79 |
Enterprise Value | -$34.93M | $1.04B |
Dividend Yield | — | 5.05% |
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.9973, up 0.23% with a bearish technical signal despite recent earnings beats. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though cash burn improved from -$33M to -$30M projected for 2026. Analyst consensus is strongly bullish with 8 buy ratings versus 4 hold ratings.
The outlook remains challenging due to persistent losses and negative cash flow, but analyst optimism and continued progress in TSC-related epilepsy therapies provide potential catalysts. Key risks include execution challenges in clinical development and the company's ability to secure additional funding.
RLX trades at $2.01, up 0.5% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported Q1 2026 revenue growth driven by international expansion, with a net income margin of 22.47% in 2026. Recent news highlights its Q2 2026 earnings call scheduled for August 14, 2026, focusing on European integration.
The outlook is mixed: strong international revenue growth and solid profitability support upside, but consecutive earnings misses and a single analyst's hold rating indicate caution. Key risks include regulatory scrutiny in the vaping industry and execution challenges in global markets.
Trailing returns across standard periods
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →RLX Technology Inc. is a leading e-vapor company in China, focusing on the research, development, and sale of e-vapor products. The company primarily operates under the RELX brand, offering a range of closed-system e-vapor products designed to deliver a high-quality user experience. RLX's business model is centered on product innovation, strong brand building, and a vast distribution network across China.
Read more on RLX →